. 2021 Feb 22;36(5):1288–1295. doi: 10.1093/humrep/deab013

Table II.

Main outcomes from the cost-effectiveness analysis (all agents).

Agent	Cumulative probability of live birth over four cycles %	Average costs (€)	Probability of multiple pregnancy %	Incremental cost-effectiveness ratio (€) (ICER) ^*
Clomiphene citrate	29.4	362	2.5	0 (reference)
Letrozole	32.0	434	3.0	2809 (95% CI: –46 462 to 41 136)
Gonadotrophins	34.5	1809	5.3	53 831 (95% CI: –294 542 to 345 764)

Agent

Cumulative probability of live birth over four cycles %

Average costs (€)

Probability of multiple pregnancy %

Incremental cost-effectiveness ratio (€) (ICER) ^*

Clomiphene citrate

29.4

362

2.5

0 (reference)

Letrozole

32.0

434

3.0

2809 (95% CI:

–46 462 to 41 136)

Gonadotrophins

34.5

1809

5.3

53 831 (95% CI:

–294 542 to 345 764)

All costs in €EUR.

Step-wise approach first comparing Letrozole to clomiphene citrate and second gonadotrophins to Letrozole.